The pancreatic cancer proteome - recent advances and future promise.
Of the common cancers, pancreatic ductal adenocarcinoma is one of the most lethal. The cancer's aggressive biology, leading to rapid dissemination, combined with a lack of clearly recognisable symptoms means that for many patients, the disease is at an advanced stage when diagnosed. The prognosis is consequently very poor, with as few as 3-5% of patients surviving 5 years. Recently, proteomic technologies have been employed in an effort to identify protein biomarkers, therapeutic targets and disease response markers for pancreatic cancer. Research has primarily relied upon pancreatic tissue samples, and body fluids such as pancreatic juice and blood serum. In this article, we will highlight the current proteomic techniques, qualitative and quantitative, employed in the field of pancreatic cancer research. We will review both the progress made and the challenges ahead, in elaborating the biology of pancreatic cancer and identifying novel biomarkers.